Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Aratana Therapeutics (PETX) Stock Price

News stories about Aratana Therapeutics (NASDAQ:PETX) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aratana Therapeutics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.4880856312586 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

A number of equities analysts have recently issued reports on PETX shares. Credit Suisse Group restated an “outperform” rating and issued a $8.00 price objective (down previously from $9.00) on shares of Aratana Therapeutics in a research note on Friday, March 16th. ValuEngine upgraded shares of Aratana Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 2nd. BidaskClub upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 10th. HC Wainwright set a $10.00 price objective on shares of Aratana Therapeutics and gave the company a “buy” rating in a research note on Monday, March 19th. Finally, Zacks Investment Research upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $8.68.

Shares of Aratana Therapeutics traded up $0.08, reaching $4.61, during mid-day trading on Friday, Marketbeat Ratings reports. 1,355,874 shares of the stock were exchanged, compared to its average volume of 438,081. The stock has a market capitalization of $231.41 million, a P/E ratio of -4.75 and a beta of 2.86. The company has a quick ratio of 2.82, a current ratio of 3.37 and a debt-to-equity ratio of 0.15. Aratana Therapeutics has a fifty-two week low of $3.67 and a fifty-two week high of $7.67.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $4.04 million during the quarter, compared to analysts’ expectations of $6.06 million. Aratana Therapeutics had a negative net margin of 168.26% and a negative return on equity of 38.97%. equities analysts anticipate that Aratana Therapeutics will post -0.6 earnings per share for the current year.

In related news, insider Peter Steven St sold 11,513 shares of the stock in a transaction dated Monday, April 30th. The shares were sold at an average price of $5.00, for a total transaction of $57,565.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.30% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply